Brain microischemic phenomena in a woman receiving bevacizumab treatment: a case report by Quattrocchi, Carlo C et al.
CASE REPORT Open Access
Brain microischemic phenomena in a woman
receiving bevacizumab treatment: a case report
Carlo C Quattrocchi
1*, Andrea M Alexandre
2, Giuseppe Tonini
3, Yuri Errante





Introduction: Several adverse events have been associated with the use of bevacizumab during the treatment of
neoplasms such as colorectal cancer, breast cancer, non-small cell lung cancer, pancreatic cancer and renal cell
carcinoma. The present case demonstrates how focal neurological symptoms lead to the magnetic resonance
imaging-based differential diagnosis between focal parenchymal metastases and microischemic phenomena, with
crucial implications for patient management.
Case presentation: We describe the case of a 37-year-old Italian Caucasian woman with metastatic colon cancer
who developed focal neurological symptoms during a chemotherapy regimen involving the use of bevacizumab.
Brain magnetic resonance imaging examination revealed millimetric lesions with restricted diffusion without
perilesional edema or contrast enhancement after gadodiamide intravenous injection, suggestive of acute
microischemic phenomena. This complication is very rare but clinically significant.
Conclusion: The differential diagnosis in patients with cancer undergoing bevacizumab treatment should include
microischemic phenomena.
Introduction
We describe the case of a patient with metastatic colon
cancer who developed focal neurological symptoms dur-
ing a chemotherapy regimen including bevacizumab.
Some millimetric lesions were detected by a first mag-
netic resonance imaging (MRI) examination and were
not detectable on the MRI examination performed six
months later. In patients with cancer undergoing bevaci-
zumab treatment, the occurrence of neurological focal
symptoms leads to an MRI differential diagnosis
between focal parenchymal metastases and microis-
chemic phenomena, with crucial decisions that must be
made for patient management.
Case presentation
A 37-year-old Italian Caucasian woman underwent a
colonscopy that revealed a polypoid formation 28cm
from the external anal margin. The biopsy showed areas
of adenocarcinoma in the context of tubulovillous and
villous adenoma with mild to severe dysplasia. Com-
puted tomography (CT) staging was negative for regio-
nal or distant metastases. Surgical removal was
performed by partial colectomy. The tumor histology
confirmed the diagnosis of adenocarcinoma with infiltra-
tion of the serosa and pathological TNM staging of
pT4pN1M0.
A follow-up CT examination three months later
revealed eight focal hepatic lesions distributed through-
out both lobes. Chemotherapy treatment with the folinic
acid, fluorouracil and oxaliplatin (FOLFOX) scheme was
started, and the patient showed a partial response after
the fourth course of treatment. She underwent surgical
resection of metastases localized at hepatic segments IV
and V. CT examination showed disease progression in
the lung and liver parenchyma six months later. Several
lines of treatment were started, including XELOX (cape-
citabine plus oxaliplatin), FOLFIRI (folinic acid, fluorour-
acil and irinotecan) and radiofrequency thermoablation,
with no response. CT showed a partial hepatic response
after 12 courses of cetuximab and irinotecan therapy, but
hepatic progression was observed after 24 courses.
Therefore, chemoimmunotherapy with bevacizumab
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FOLFOX was started, but it was suspended after nine
cycles as the patient developed left hemiparesis, hemifa-
cial left anesthesia and right-hand paresthesia.
A brain MRI scan showed three millimetric lesions
located in the right temporooccipital lobe (Figure 1A),
the left pontine region (Figure 2B) and the right parietal
lobe (Figure 2C) with restricted diffusion (Figures 1A to
1C) and no enhancement after gadodiamide injection.
These findings, that is, hyperintensity on fluid attenu-
ated inversion recovery (FLAIR) images, slight enhance-
ment on postgadolinium T1-weighted images, restricted
Figure 1 (A) Right temporooccipital lesion can be easily detected as a hyperintense spot in T1-weighted sequences. (B) The lesion
shows restricted diffusion, an absence of perilesional edema. (C) No enhancement is observed after gadodiamide injection. These findings are
suggestive of areas of microischemic phenomena.
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of areas of acute microischemic strokes. Although unu-
sual in the context of stroke, the subcortical lesion at
the level of the right temporooccipital white matter was
confirmed to be unchanged with regard to size and
signal intensity on FLAIR images obtained at the one-
year follow-up examination (Figure 3). Moreover, other
bilateral centrum semiovale lesions not detected on dif-
fusion-weighted images and not showing contrast
enhancement were hypointense with a hyperintense
Figure 2 Other lesions suggestive of areas of acute embolic strokes are (A) the right parietal lobe, (B) the left pontine region and (C)
the right parietal lobe (alternate view). (D) Another bilateral centrum semiovale lesion not detected on diffusion-weighted images, without
contrast enhancement, is hypointense in this fluid attenuated inversion recovery (FLAIR) image with a hyperintense gliotic peripheral ring,
suggestive of small vascular ischemic microlacunae.
Quattrocchi et al. Journal of Medical Case Reports 2011, 5:84
http://www.jmedicalcasereports.com/content/5/1/84
Page 3 of 5gliotic peripheral ring visualized on FLAIR images,
suggestive of areas of chronic microischemic origin
(Figure 2D). These lesions appeared as millimetric spots
of hyperintensity on T2-weighted images obtained at
the one-year follow-up examination. No other risk fac-
tors for thromboembolic events were recognized: the
patient’s clinical history was negative for hypertension,
hypercholesterolemia, hypertriglyceridemia, diabetes,
obesity, smoking, atrial fibrillation, heart disease, atrial
or ventricular septal defects and previous episodes of
thrombosis or symptoms correlated to thrombosis. Her
pharmacological history was negative for anticoagulant
or procoagulant drugs. Her platelets were 161 × 10
3/μL
(normal range, 150 to 450), her International Normal-
ized Ratio was 1.08 (normal range, 0.85 to 1.16) and her
activated partial thromboplastin time ratio was 0.84
(normal range, 0.82 to 1.20).
An ultrasound Doppler study was obtained, which
showed normal morphology of supraaortic vessels. In
addition, the patient’s electrocardiogram and echocar-
diogram were normal.
Low-molecular-weight heparin (6,000 IU twice daily),
edema therapy (8 mg of dexamethasone twice daily) and
antiplatelet therapy (200 mg/day aspirin) were adminis-
tered, resulting in complete resolution of the patient’s
neurological symptoms.
Discussion
Bevacizumab, a humanized antibody directed against the
vascular endothelial growth factor (VEGF) that is used as
an angiogenesis inhibitor, has been examined in combi-
nation with chemotherapeutic agents in several clinical
trials in patients with advanced colorectal cancer [1],
even as a first-line treatment [2]. The addition of bevaci-
zumab increased the overall response rate and extended
median survival. In the past four years, bevacizumab has
been used with increasing frequency for the treatment of
other neoplasms, such as breast cancer, non-small cell
lung cancer, pancreatic cancer and renal cell carcinoma.
Several adverse events have been associated with the
use of bevacizumab: hypertension (the most common
side effect), gastrointestinal perforation, wound-healing
complications, hemorrhage, arterial thomboembolic
events, proteinuria, congestive heart failure, leukopenia
and diarrhea [3]. Arterial thromboembolic events have
been observed in 0.9% of the cases in the BEATrial [3]
and in 2.1% of the cases in the BRiTE Registry [4]. The
mechanism of concurrent thrombosis and bleeding dur-
ing bevacizumab treatment is not clear, being related to
the role of VEGF in maintaining a healthy endothelium.
Conclusion
Vascular events involving the central nervous system
have been reported as reversible posterior leukoence-
phalopathy syndrome following a bevacizumab or FOL-
FIRI treatment regimen for metastatic colon cancer,
which are likely related to high systolic blood pressure
levels [5]. Furthermore, as thromboembolic events and
microischemic phenomena are a well-known complica-
tion of bevacizumab chemotherapeutic treatment [6],
the occurrence of neurological focal symptoms leads to
an MRI-based differential diagnosis between focal par-
enchymal metastases and microischemic phenomena,
which lead to crucial decisions for patient management.
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Figure 3 FLAIR image obtained at the patient’s one-year
follow-up magnetic resonance imaging (MRI) examination
demonstrating the subcortical lesion at the level of the right
temporooccipital white matter. The lesion was unchanged with
regard to size and signal intensity compared with the previous MRI
(see Figure 1A).
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